Involvement of Lipid Mediators in the Pathogenesis of Experimental Nephrosis in Rats: Its Pharmacological Modulation

References

• Fajardo L F, Elhingham J K, Stewart J R, Klauber M K. Adriamycin nephrotoxicity. Lab Invest 1980; 43: 242–253
   PubMed Web of Science ®Google Scholar
• Bertani T, Poggi A, Pozzoni R, Delaini F, Sacchi G, Thona Y, Mecca G, Remuzzi G, Donati M B. Adriamycin-induced nephrotic syndrome in rats: Sequence of pathologic events. Lab Invest 1982; 46: 16–23
   PubMed Web of Science ®Google Scholar
• Remuzzi G, Zoja C, Remuzzi A, Rossini M, Battaglia C, Broggini M, Bertani T. Low-protein diet prevents glomerular damage in Adríamycin-treated rats. Kidney Int 1985; 28: 21–37
   PubMedGoogle Scholar
• Lianos E A. Eicosanoids and the modulation of glomerular immune injury. Kidney Int 1989; 35: 985–992
   PubMed Web of Science ®Google Scholar
• Remuzzi G, Imberti L, Rossini M, Morelli C, Carminati C, Cattaneo G M, Bertani T. Increased glomerular thromboxane synthesis as a possible cause of proteinuria in experimental nephrosis. J Clin Invest 1985; 75: 94–101
   PubMedGoogle Scholar
• Lianos E A. Synthesis of hydroxyeicosatetraenoic acids and leukotrienes in rat nephrotoxic serum glomerulonephritis: Role of anti-glomerular basement membrane antibody dose, complement and neutrophils. J Clin Invest 1988; 82: 427–435
   PubMedGoogle Scholar
• Lianos E A, Noble B. Glomerular arachidonate 5-lipoxynation in active and passive Heymann nephritis. Kidney Int 1987; 31: 277, (A)
   Google Scholar
• Pinckard R N, Ludwig J C, McManus L M. Platelet activating factors. Inflammation:: Basic Principles and Clinical Correlates, I I Gallin, I M Goldstein, R Snyderman. Raven Press, New York 1988; 139–167
   Google Scholar
• Schlondorff D, Neuwirth R. Platelet activating factor in the kidney. Am J Phisiol 1986; 251: F1–F11
   Google Scholar
• Camussi G. Potential role of platelet-activating factor in renal pathophysiology. Kidney Int 1986; 29: 469–477
   PubMed Web of Science ®Google Scholar
• Egido J, Ramirez F, Rodriguez M J, Robles A, Ortiz A, Pirotzky E, Mampaso F, Braquet P. The role of platelet activating factor in glomerular kidney diseases. New Trends in Lipid Mediators Res, P Brqaquet. Karger, Basel 1988; Vol 2: 167–180
   Google Scholar
• Egido J, Robles A, Ortiz A, Ramirez F, González E, Mampaso F, Sánchez Crespo M, Braquet P. Role of platelet activating factor in Adriamycin-induced nephropathy in rats. Eur J Pharmacol 1987; 138: 119–123
   PubMed Web of Science ®Google Scholar
• Chaumet-Riffaud Ph, Oudinet J P, Sraer J, Lajotte Ch, Ardaillou R. Altered PGE2 and PGF2 production by glomeruli and papilla of sodium-depleted and sodium-loaded rats. Am J Physiol 1981; 241: F517–F524
   Google Scholar
• Sánchez-Crespo M, Iñarrea P, Alvarez V, Alonso F, Egido J, Hernando L. Presence in normal human urine of a hypotensive and platelet activating phospholipid. Am J Physiol 1983; 244: F706–F711
   Google Scholar
• Schlondorff D, Roczniak S, Satriano J A, Folkert V W. Prostaglandin synthesis by isolated glomeruli: effect of angiotensin II. Am J Physiol 1980; 238: F486–F495
   Google Scholar
• Sánchez-Crespo M, Alonso F, Iñarrea P, Alvarez V, Egido J. Vascular actions of synthetic PAF—acether (a synthetic platelet-activating factor) in the rat: Evidence for a platelet-independent mechanism. Immunopharmacology 1982; 4: 173–185
   PubMed Web of Science ®Google Scholar
• Camussi G, Tetta C, Coda R, Segoloni G P, Vercellone A G. Platelet activating factor induced loss of glomerular anionic charges. Kidney Int 1984; 25: 73–81
   Google Scholar
• Perico N, Delaini F, Tagliaferri M, Abbate M, Cucchi M, Bertani T, Remuzzi G. Effect of platelet activating factor and its specific receptor antagonist on glomerular permeability to proteins in isolated perfused rat kidney. Lab Invest 1988; 58: 163–171
   PubMedGoogle Scholar
• Schlondorff D, Goldwasser P, Neuwirth R, Satriano J A, Clay K L. Production of platelet activating factor in glomeruli and cultured glomerular mesangial cells. Am J Physiol 1986; 250: F1123–F1127
   Google Scholar
• Mampaso F M, Egido J, Martinez-Montero J C, Bricio T, González E, Cobo M E, Pirotzky E, Braquet P, Hernando L. Interstitial mononuclear cell infiltrates in experimental nephrosis: Effect of PAF antagonist. Nephrol Dial Transplant 1989; 4: 1037–1044
   PubMed Web of Science ®Google Scholar
• Braquet P. Involvement of PAF—acether in various immune disorders using BN 52021 (ginkgolide B): a powerful PF—acether antagonist isolated from ginkgo biloba. Advances in Prostaglandin, Thromboxane and Leucotrien, V Zopr. Raven Press, New York 1986; Vol 16: 179–198
   Google Scholar
• Braquet P, Shen T Y, Touqui L, Vargaftig B B. Perspectives in platelet-activating factor research. Pharmacol Rev 1987; 39: 97–145
   PubMed Web of Science ®Google Scholar
• Ardaillou R, Baud L, Chansel D, Sracr J. The role of lipoxygenase products of arachidonate metabolism in the control of glomerular functions. Nephrology, Vol 1 (Proceedings of the Xth International Congress of Nephrology), A M Davison. London 1989
   Google Scholar
• Rahman M A, Nakazawa M, Emancipator M J, Dunn M J. Increased leukotriene B4 synthesis in immune injured rat glomeruli. J Clin Invest 1988; 81: 1945–1952
   PubMedGoogle Scholar
• Cluzel M, Undem B J, Chilton F H. Release of platelet-activating factor and the metabolism of leukotriene B4 by the human neutrophil when studied in a cell superfusion model. J Immunol 1989; 143: 3659–3665
   Google Scholar
• Lin A H, Morton D R, Gorman R R. Acetyl glyceryl ether phosphorylcholine stimulates leukotriene B4 synthesis in human polymorphonuclear leukocytes. J Clin Invest 1982; 70: 1058–1064
   PubMed Web of Science ®Google Scholar
• Dallob A, Guindon Y, Goldenberg M. Pharmacological evidence for a role of lipoxygenase products in platelet-activating factor (PAF)-induced hyperalgesia. Biochem Pharmcol 1987; 36: 3201–3204
   Google Scholar